Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - methotrexate - solution for infusion or injection - methotrexate 25 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

strides arcolab international limited - methotrexate 25 mg/ml - solution for infusion or injection

Malta - English - Medicines Authority

accord healthcare limited - methotrexate - solution for injection - methotrexate 25 mg/ml - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide - antineoplastic chemotherapy - methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. methotrexate may be used in combination with other chemotherapeutic agents for the palliative treatment of acute leukaemias, particularly acute lymphoblastic leukaemia. it may also be used in the treatment of burkitt's lymphoma, advanced stages (iii and iv, peters' staging system) of lymphosarcoma, especially in children, and in advanced cases of mycosis fungoides. high dose therapy - in high-dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy (see warning box) - methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (all) as part of a combination chemotherapy regimen. methotrexate injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. methotrexate injection is indicated for the treatment of adults and pediatric patients with non-hodgkin lymphoma. methotrexate injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. methotrexate injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen. methotrexate injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single-agent. methotrexate injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (gtn) as part of a combination chemotherapy regimen. methotrexate injection is indicated for

Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - methotrexate - solution for infusion or injection - methotrexate 25 mg - antineoplastic agents

Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - methotrexate - solution for infusion or injection - methotrexate 25 mg - antineoplastic agents

Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - methotrexate - solution for infusion or injection - methotrexate 25 mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - methotrexate 20 mg/ml - injection with diluent - 20 mg/ml - active: methotrexate 20 mg/ml excipient: sodium chloride sodium hydroxide water for injection - - active rheumatoid arthritis in adult patients where treatment with disease modifying antirheumatic drugs (dmards) is indicated. - polyarthritic forms of severe, active juvenile idiopathic arthritis (jia) when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate - severe forms of psoriasis vulgaris, particularly of the plaque type, which cannot be sufficiently treated with conventional therapy such as phototherapy, puva, and retinoids, and severe psoriatic arthritis.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - methotrexate 100 mg/ml - concentrate for injection - 100 mg/ml - active: methotrexate 100 mg/ml excipient: sodium hydroxide water for injection - antineoplastic chemotherapy. methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer and the palliation of acute and subacute lymphocytic leukaemia (greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias). methotrexate is now most commonly used for the maintenance of medicine induced remissions. high dose therapy. in high dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy. methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatological consultation.